Home › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

What's Popular?

In Cancer

  1. China FDA Approves Novogene CDx Test for NSCLC Therapies

  2. Natera Partners With Fox Chase to Evaluate ctDNA Cancer Assay

  3. Genetic Technologies Announces Planned Chinese Joint Venture

  4. MDxHealth Hopes to Build Lead in Prostate Risk Testing With Utility Evidence for SelectMDx

    Premium

  5. GeneNews Posts 88 Percent Decline in Q2 Revenues; Inks Liquid Biopsy Alliance With LifeX

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.